Bellicum Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Houstontexasfounded In 2004The Company Specializes In Developing And Commercializing Innovative Cellular Immunotherapies Aimed At Treating Various Cancers And Orphan Inherited Blood Disordersbellicum Operates Both In The United States And Internationally The Company Employs Its Proprietary Chemical Induction Of Dimerizationcidtechnology Platform To Engineer Immune System Componentsthis Technology Supports The Development Of Next Generation Therapiesincluding Car T And Tcr Cell Therapiesas Well As Hematopoietic Stem Cell Transplantationbellicum S Product Pipeline Features Candidates Like Bpx 601 And Bpx 603Both In Phase 1 2 Clinical Trials For Treating Solid Tumors Bellicum Has Formed Strategic Collaborations With Several Organizationsincluding Adaptimmune Therapeutics And Baylor College Of Medicineto Enhance Its Research And Development Efforts In Cellular Immunotherapy
